Business Context and Reporting Period
IDEXX Laboratories, Inc. filed an unaudited Form 10-Q for the three months ended March 31, 2020. The company provides veterinary diagnostic products and services, veterinary software and information-management solutions, water-testing products, livestock and poultry diagnostics, and human medical diagnostics. Its primary segments are Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.
The filing was prepared during the COVID-19 pandemic. Veterinary, manufacturing, distribution, and reference-laboratory operations were generally treated as essential, but stay-at-home policies reduced companion-animal clinical visits, particularly elective and wellness procedures.
Financial Performance and Position
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Total revenue | $626.3 million | $576.1 million | 8.7% |
| Gross profit | $359.6 million | $331.6 million | 8.4% |
| Gross margin | 57.4% | 57.6% | Down 20 bps |
| Income from operations | $144.3 million | $133.1 million | 8.4% |
| Operating margin | 23.0% | 23.1% | Down 10 bps |
| Net income | $111.9 million | $102.7 million | 8.9% |
| Net income attributable to IDEXX shareholders | $111.8 million | $102.7 million | 8.9% |
| Diluted EPS | $1.29 | $1.17 | 10.3% |
| Net cash from operating activities | $27.9 million | $34.4 million | Down $6.5 million |
| Capital expenditures and intangible-asset purchases | $49.7 million | $38.2 million | Use increased $11.5 million |
CAG generated $552.0 million of revenue, up 8.5% reported and 8.6% organically. Water revenue was $34.1 million, up 12.7% reported and 15.4% organically. LPD revenue was $34.2 million, up 8.4% reported and 12.0% organically. Other revenue was $6.0 million, up 13.4%.
CAG recurring revenue increased 9.9%, led by IDEXX VetLab consumables and reference-laboratory services. CAG capital-instrument revenue declined 17.1%, reflecting deferred customer orders, COVID-19 effects, product mix, and lower SediVue Dx placements.
At March 31, 2020, cash and cash equivalents were $81.4 million, compared with $90.3 million at December 31, 2019. Accounts receivable were $300.0 million and inventories were $211.6 million. The allowance for accounts receivable credit losses increased to $7.0 million from $3.6 million at year-end.
Debt included $486.8 million outstanding under the revolving credit facility and $697.4 million of long-term debt, for reported debt of approximately $1.18 billion. Gross debt to trailing-twelve-month Adjusted EBITDA was 1.70x and net debt to Adjusted EBITDA was 1.59x; the company was in compliance with its 3.5x leverage covenant.
Material Changes Versus the Prior Comparable Period
- Revenue increased $50.3 million, with organic growth of 9.2% for the company. Currency reduced reported revenue growth by 1.1 percentage points.
- Gross and operating margins modestly declined because of currency, COVID-19-related reductions in reference-laboratory volume, incremental reference-laboratory capacity, and the Marshfield laboratory acquisition.
- Operating cash flow decreased despite higher net income, primarily because of working-capital uses, including higher employee incentive payments, taxes, accounts receivable, and other assets and liabilities.
- Cash used for investing increased, principally because of higher capital spending related to purchasing a previously leased reference-laboratory facility.
- Financing cash flow improved to $16.9 million from a $2.8 million use in the prior year, largely because of $198.1 million of net revolving-credit borrowings. Share repurchases increased to $182.8 million from $54.3 million.
- The company adopted the expected-credit-loss standard, ASU 2016-13, on January 1, 2020, recording a $1.8 million net reduction to opening retained earnings.
- Beginning in 2020, management changed segment cost allocations. This affects segment comparability, although consolidated results were not changed.
Guidance, Outlook, Commentary, Risks, and Unusual Items
The filing does not provide a clear numerical full-year revenue or earnings guidance range. Management stated that COVID-19 effects were difficult to predict and that quarterly results were not necessarily indicative of full-year performance.
- Management cited U.S. companion-animal practice data showing year-over-year declines of 15% to 30% in per-practice clinical visits from the week ended March 27 through the week ended April 24, 2020. Diagnostic-testing trends improved during the two weeks ended April 24 as certain regions moderated restrictions.
- Management advanced actions intended to reduce quarterly operating expenses by approximately $25 million versus original plans, including temporary salary reductions for executives and other salaried employees and suspension of board cash compensation.
- In April 2020, the company suspended share repurchases, issued $200 million of 10-year senior notes bearing 2.50% interest, and expanded and extended its revolving credit facility to $1.0 billion through 2023, with an option to increase commitments to $1.25 billion subject to conditions.
- The company offered certain independently owned veterinary customers an additional 30 days to pay amounts due, which may increase days sales outstanding and operating cash requirements.
- COVID-19 risks include lower veterinary demand, delayed or canceled customer orders, collection difficulties, inventory expiration, supply-chain disruption, workforce limitations, increased healthcare costs, liquidity pressure, covenant risk, and potential goodwill or intangible-asset impairment.
- Goodwill impairment was not indicated as probable at March 31, 2020, but management noted that a prolonged downturn or sustained stock-price decline could require an interim impairment review.
- Legal accruals were not material, and management reported no significant changes to previously disclosed contingencies. The filing states that actual losses could exceed recorded accruals.
Important Facts for Investors to Verify
- Whether reduced veterinary visits and deferred elective procedures materially affected CAG recurring revenue after March 31, 2020.
- Whether the announced $25 million quarterly cost reductions were achieved and how much was temporary versus structural.
- Post-quarter liquidity, revolver utilization, interest expense, and compliance with the 3.5x leverage covenant after the April debt financings.
- Accounts receivable aging, customer-payment extensions, credit-loss reserves, and cash conversion as the pandemic continued.
- Any subsequent changes to capital spending, share repurchases, customer-acquisition costs, contract assets, or goodwill impairment assessments.
- The effect of the changed segment-cost allocation methodology when comparing 2020 segment margins with prior periods.
- Any formal full-year guidance issued after the filing, as this 10-Q does not provide a clear numerical guidance range.